NICE阿替普酶溶栓指南.pdf

Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122) Issued: September 2012 NICE technology appraisal guidance 264 .uk/ta264 NHS Evidence has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and applies to guidance produced since June 2008 using the processes described in NICEs The guide to the methods of technology appraisal (2008). More information on accreditation can be viewed at www.evidence.nhs.uk © NICE 2012 Alteplase for treating acute ischaemic stroke (review of NICE technology appraisal guidance 264 technology appraisal guidance 122) Contents 1 Guidance 3 2 The technology 4 3 The manufacturers submission 5 4 Consideration of the evidence 15 Summary of Appraisal Committees key conclusions 20 5 Implementation28 6 Recommendations for further research 29 7 Related NICE guidance 30 8 Review of guidance 31 Appendix A: Appraisal Committee members and NICE project team 32 A Appraisal Committee members 32 B NICE project team34 Appendix B: Sources of evidence considered by the Committee 35 About this guidance 36 © NICE 2012. All rights reserved. Last modified September 2012 Page 2 of 37 Alteplase for treating acute ischaemic stroke (review of NICE technology appraisal guidance 264 technology appraisal guidance 122) 1 Guidance This guidance replaces NICE technology appraisal guidance 122 (published in June 2007). For details see About this guidance . 1.1 Alteplase is recommended within its marketing authorisation for treating acute ischaemic stroke in adults if:  treatment is s